期刊文献+

第4代头孢菌素头孢吡肟的耐药性及耐药危险因素 被引量:9

Drug Resistance the Fourth Generation Cephalosporin Cefepime and Its Risk Factors
下载PDF
导出
摘要 目的:探索第4代头孢菌素头孢吡肟耐药危险因素,为临床合理治疗及应用抗菌药物提供依据。方法:以唐山市中医医院细菌室做细菌培养及药敏实验的765例患者共984株耐药菌为本次研究对象,对患者病历做回顾性调查,用SPSS 10.0进行统计学分析,χ2检验用于比较各组间率的差异。结果:共培养分离出耐药菌984株,以革兰阴性杆菌为主,占64.7%,头孢吡肟总耐药率为48.77%,除对嗜麦芽假单胞菌、肠球菌天然耐药外,对其他细菌耐药率在25%~65%之间,结论:不同细菌对头孢吡肟的耐药率不尽相同,但近年来其耐药率有上升趋势。耐药危险因素是混合感染、抗菌药物使用时间≥4周。 OBJECTIVE:To explore the risk factors for drug resistance of cefepime-the fourth generation cephalosporin so as to provide reference of clinical rational treatment and use of antibiotic.METHODS: Our study was performed on a total of 984 strains of resistant bacteria isolated from 765 patients whose samples underwent bacterial culture and drug susceptibility test in the bacterial testing room of Tangshan Hospital of Traditional Chinese Medcine.A retrospective study was performed on patients' case records with statistical analysis made using SPSS 10.0 and the rate differences among groups compared using χ2 test.RESULTS: A total of 984 resistant strains were isolated,of which,64.7% were gram negative bacilli.The total drug resistant rate of cefepime was 48.77%.Cefepime has natural drug resistance to Pseudomonas maltophilia and E.coli,and it had a drug resistant rate of 25%-65% to all the other bacteria except Pseudomonas maltophilia and E.coli.CONCLUSION: The antibiotic resistant rates of cefepime to different bacteria are different.However,recently,the drug resistant rate of cefepime shows an upward trend.The risk factors for the antibiotic resistance include mixed infection and the prolonged use of antibiotics(≥4 weeks).
出处 《中国医院用药评价与分析》 2010年第12期1092-1094,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 头孢吡肟 耐药 危险因素 Cefepime Drug resistance Risk factor
  • 相关文献

参考文献3

二级参考文献21

  • 1宋志芳,景炳文.综合ICU各种感染菌群分析[J].中国危重病急救医学,1993,5(6):334-336. 被引量:15
  • 2邢旺兴.β-内酰胺酶的基本特性及其检验方法[J].国外医药(抗生素分册),1995,16(6):408-414. 被引量:12
  • 3Murray PR , Baron EJ, Pfaller MA, et al. Manual of Clinical microbiology 7th ed. American society for microbiology, Washington, D.C.1999, 262-560.
  • 4National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 12th inform suppl. M2-A7 and M7-A5.National Committee for Clinical Laboratory Standards, Wayne, pa, 2002, 42-49.
  • 5Naumiuk L, Samer A, Dziemaszkiewicz E. Cefepime in vitro activity against derepressed extended-spectrum β-lactamase(ESBL)-producing and non-ESBL-producing Enterobacter cloacae by a disc diffusion method. J Antimicrob Chemother, 2001,48:321-322.
  • 6Empey KM, Rapp RP, Evans ME.The effect of an antimicrobial formulary change on hospital resistance patterns. Pharmacotherapy, 2002,22:81-87.
  • 7Pfaller, MA, Jones, RN, Doern, GV, et al. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Cana
  • 8Giamarellou H Fourth generation cephalosporins in the antimicrobial chemotherapy of surgical infectionsJ Chemother, 1999,11:486-493.
  • 9Corbella X, Montero A, Pujol M, et al. Emergence and rapid spread of Carbapenem resistance during a large ang sustained hospital outbreak of multiresistant Acinetobacter baumannii [J]. J Clinical Microbiology ,2000,38( 11 ) :4 086.
  • 10Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among Gram -negative bacilli in US Intensive Care Units[J]. JAMA ,2003,289(7) :885.

共引文献30

同被引文献73

引证文献9

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部